Genefirst Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Private

  • Employees
  • 15

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $1.85M

  • Investors
  • 4

Genefirst General Information

Description

Developer of biotechnology research company designed to develop molecular diagnostics kits and devices to aid the diagnosis of diseases. The company's devices are sensitive, and affordable molecular diagnostics technologies and products that can be used in the fields of infectious disease, cancer diagnostics, and personalized medicine for the simultaneous detection of multiple targets in one reaction, enabling researchers, clinicians, and drug companies to get accurate diagnoses with the delivery of safer and effective medicines.

Contact Information

Website
www.genefirst.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Diagnostic Equipment
Other Industries
Biotechnology
Primary Office
  • Unit 2 The Quadrant, Abingdon Science Park
  • Oxfordshire
  • Abingdon OX14 3YS
  • England, United Kingdom
+44 01865 000000

Genefirst Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Genefirst Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Grant 01-Aug-2020 $1.85M 00.00 Completed Generating Revenue
9. Later Stage VC (Series A) 19-Mar-2020 00.000 00.00 000.00 Completed Generating Revenue
8. Grant 01-Oct-2018 00.000 00.000 Completed Generating Revenue
7. Grant 01-Mar-2018 00000 00.000 Completed Generating Revenue
6. Grant 01-Feb-2018 00000 00.000 Completed Generating Revenue
5. Grant 26-Oct-2017 00000 00.000 Completed Generating Revenue
4. Grant 01-Jan-2017 000.00 00.000 Completed Generating Revenue
3. Seed Round 07-Jan-2015 00.000 00.000 00.00 Completed Generating Revenue
2. Grant 01-Aug-2014 $42.6K Completed Generating Revenue
1. Corporate 01-Jan-2014 Completed Generating Revenue
To view Genefirst’s complete valuation and funding history, request access »

Genefirst Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Preference 000,000 00.000000 00.00 00.00 00 00.00 00.000
Series A Preferred 00,000 00.000000 00.00 00.00 00 00.00 0.000
Series A Preferred 587,500 $0.000127 $4.56 $4.56 1x $4.56 28.2%
Ordinary 49,380 $0.000127 $3.1 $3.1 1x $3.1 2.37%
To view Genefirst’s complete cap table history, request access »

Genefirst Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of biotechnology research company designed to develop molecular diagnostics kits and devices to aid the diagno
Diagnostic Equipment
Abingdon, United Kingdom
15 As of 2023
00.00
0000000000 00.00

000000

a pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui of
0000000000 000000000
Redmond, WA
00 As of 0000
000000&0

0000 0

t nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa
0000000000 000000000
Cambridge, United Kingdom
0 As of 0000
000.00
0.000 0000-00-00
000000&0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Genefirst Competitors (12)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Resolution Bioscience Formerly Angel backed Redmond, WA 00 000000&0
0000 0000 Formerly VC-backed Cambridge, United Kingdom 0 000.00 000000&0 000.00
000000 000 Venture Capital-Backed Cambridge, United Kingdom 00 000 00000 00000
000000000 Formerly VC-backed Rostock, Germany 000 00000 000000000 00000
00000000 Pending Transaction (M&A) Irvine, CA 00 000.00 000000000 000.00
You’re viewing 5 of 12 competitors. Get the full list »

Genefirst Patents

  • 30

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 2

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

Genefirst Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202308392-D0 Methods, compositions, and kits for preparing library and targeted sequencing Pending 06-Jun-2023
GB-202108427-D0 Methods, compositions, and kits for preparing sequencing library Inactive 14-Jun-2021 0000000000
GB-201719114-D0 Methods, compositions, and kits for preparing library and targeted sequencing Inactive 17-Nov-2017
GB-201708384-D0 Methods, compositions, and kits for preparing library and targeted sequencing Inactive 25-May-2017
GB-201707259-D0 A biological carrier for delivering proteins or peptides as medicine or vaccine Inactive 05-May-2017
To view Genefirst’s complete patent history, request access »

Genefirst Executive Team (3)

Name Title Board Seat Contact Info
Guoliang Fu Co-Founder & Chief Executive Officer
Andrew Wood Chief Financial Officer
Winnie Wu Chief Operations Officer
To view Genefirst’s complete executive team members history, request access »

Genefirst Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Genefirst Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
National Institute for Health Research Government 000 0000 000000 0
Horizon 2020 SME Instrument Government Minority 000 0000 000000 0
Innovate UK Government 000 0000 000000 0
Fosun Pharma Corporation Minority 000 0000 000000 0
To view Genefirst’s complete investors history, request access »

Ready to get started?

Request a free trial